Ubidecarenone (BAN, rINN)
Coenzyme Q10; Ubidecarenona; Ubidécarénone; Ubidecarenonum; Ubidekarenon; Ubidekarenonas; Ubidekarenoni; Ubiquinone-10. 2-Deca(3-m
Pharmacopoeias. In Chin., Eur. (see p.vii), Jpn, and US. Ph. Eur. 6.2 (Ubidecarenone). A yellow or orange crystalline powder. It gradually decomposes and darkens on exposure to light. M.p. about 48°. Practically insoluble in water; very slightly soluble in dehydrated alcohol; soluble in acetone. Store in airtight containers. Protect from light.
USP 31 (Ubidecarenone). A yellow to orange, crystalline powder. M.p. about 48°. Practically insoluble in water; very slightly soluble in dehydrated alcohol; soluble in ether. Protect from light.
Ubidecarenone is a naturally occurring coenzyme involved in electron transport in the mitochondria. It is claimed to be a free radical scavenger and to have antoxidant and membrane stabilising
properties. It has been given by mouth as an adjunct in cardiovascular disorders, including mild or moderate heart failure. It has also been tried in other conditions associated with coenzyme deficiency, and is promoted as a dietary supplement. Ubidecarenone is under investigation for the management of cancer,
Huntington’s chorea (p.953) and parkinsonism.
1. Greenberg S, Frishman WH. Co-enzyme Q : a new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596–608.
2. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994; 344: 1372–3. 3. Garcia Silva MT, et al. Improvement of refractory sideroblastic anaemia with ubidecarenone. Lancet 1994; 343: 1039. 4. Gattermann N, et al. No improvement of refractory sideroblast- ic anaemia with ubidecarenone. Lancet 1995; 345: 1121–2. 5. Nagao T, et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995; 346: 1104–5. 6. Pepping J. Coenzyme Q . Am J Health-Syst Pharm 1999; 56: 519–21. 7. Khatta M, et al. The effect of coenzyme Q in patients with
congestive heart failure. Ann Intern Med 2000; 132: 636–40.
8. Tran MT, et al. Role of coenzyme Q10 in chronic heart failure,
angina, and hypertension. Pharmacotherapy 2001; 21: 797–806.
9. Huntington Study Group. A randomized, placebo-controlled trial
of coenzyme Q10 and remacemide in Huntington’s disease.
Neurology 2001; 57: 397–404. 10. Rahman S, et al. Neonatal presentation of coenzyme Q10 deficiency.
J Pediatr 2001; 139: 456–8. 11. Roffe L, et al. Efficacy of coenzyme Q10 for improved tolerability
of cancer treatments: a systematic review. J Clin Oncol 2004; 22: 4418–24. 12. Sándor PS, et al. Efficacy of coenzyme Q10 in migraine prophylaxis:
a randomized controlled trial. Neurology 2005; 64: 713–15. 13. Levy HB, Kohlhaas HK. Considerations for supplementing with
coenzyme Q during statin therapy. Ann Pharmacother 2006; 40: 290–4.
14. The NINDS NET-PD Investigators. A randomized clinical trial
of coenzyme Q and GPI-1485 in early Parkinson disease. Neu- rology 2007; 68: 20–8.
15. Rosenfeldt FL, et al. Coenzyme Q in the treatment of hypertension:
a meta-analysis of the clinical trials. J Hum Hypertens
2007; 21: 297–306.